
PAVmed (PAVM) Stock Forecast & Price Target
PAVmed (PAVM) Analyst Ratings
Bulls say
PAVmed Inc. has demonstrated solid growth in its EsoGuard testing volume, processing 2,841 tests in Q3, reflecting an increase from previous quarters, indicating a positive trend in its diagnostic business. The company's current valuation is considered attractive, balancing its inherent risks with substantial upside potential, suggesting a favorable investment scenario. Additionally, the expected significant growth in PAVmed's commercialized products, including EsoGuard, Esocheck, and the Veris Cancer Care Platform, positions the company for continued success in the medical technology sector in the near future.
Bears say
PAVmed Inc has reported a pro forma net loss of $0.8 million, highlighting ongoing financial struggles, as this figure is significantly below the consensus estimate range for earnings per share, which was between $(0.13) and $(0.25). Additionally, a decline in the number of EsoGuard tests processed, from 3,034 in Q1 to 2,756 in Q2, raises concerns about demand and growth potential in this critical segment of the business. The company's early-stage products, including the Lucid business and Veris platform, contribute to low current revenue levels, while various risks, including liquidity challenges and regulatory hurdles, further underscore the negative outlook on the stock.
This aggregate rating is based on analysts' research of PAVmed and is not a guaranteed prediction by Public.com or investment advice.
PAVmed (PAVM) Analyst Forecast & Price Prediction
Start investing in PAVmed (PAVM)
Order type
Buy in
Order amount
Est. shares
0 shares